Full Press Release Details
– Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life
– Published findings demonstrate favorable safety and tolerability profile of donidalorsen in Phase 2 study
– Donidalorsen is one of Ionis' wholly owned medicines the company plans to commercialize
CARLSBAD, Calif.,March 16, 2022/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq:IONS), the leader in RNA-targeted therapies, today announced the publication of positive Phase 2 data for donidalorsen (formerly IONIS-PKK-LRx) in theNew England Journal of Medicine (NEJM)available atNEJM.org. Donidalorsen is an investigational antisense medicine Ionis is evaluating for treating patients with hereditary angioedema (HAE). In the Phase 2 study, donidalorsen demonstrated a 90% reduction in angioedema attacks compared with placebo at the 80 mg monthly dose. There was significant improvement in quality of life as assessed by the Angioedema Quality of Life Questionnaire (AE-QoL) in the patients treated with donidalorsen.